I’ve been using *Wobenzym since 2013 and have seen incredible results in people having a reduction (sometimes even an elimination) of thyroid antibodies and food sensitivities!
I had a chance to meet Dr. Collins at the Key Opinion Leaders Summit for Atrium Innovations, the parent company of Pure Encapsulations and Wobenzym in the fall of 2016.
I’ve been using Pure Encapsulations products since 2011. As a pharmacist, I was very skeptical of supplements but did my research and learned about all of the extensive testing done by Pure Encapsulations to ensure product quality and purity and decided to give their products a try. I’m really glad that I did because their supplements helped me recover my health! One enzyme in particular, Betaine with Pepsin, was a game changer for me early on in my journey, helping me recover from almost a decade of chronic fatigue virtually overnight!
I was introduced to the Pure Encapsulations leadership in early 2016 by Tom Blue, from the Institute of Functional Medicine, and was excited to learn that the people who make the high-quality, hypoallergenic products that I love so much are really amazing and caring people as well!
I’m proud to announce that I was recently invited to become an advisor to the company, which is amazing because I now have the opportunity to provide advice on what types of products I’d like to see from Pure Encapsulations for the autoimmune thyroid community!! I’d also like to add that I’m the youngest woman and the only PharmD on their advisory committee 🙂
I had a chance to connect with another one of the advisors, Dr. Collins, and I was so impressed with his knowledge about thyroid disease and systemic enzymes that I immediately asked (begged?) him to be a part of The Thyroid Secret!
My goal in creating this documentary was to get the top thyroid experts together to share the best innovation each of them is seeing so that together we can really move the conversation about recovering from thyroid disorders forward.
Now, here is a guest blog post from Dr. Joe Collins about the impact of thyroid antibodies and Wobenzym.
By: Dr. Joe Collins
One of the goals of treating and managing autoimmune thyroid disease is to bring the patient back to a euthyroid (“Normal Thyroid”) state. Euthyroid is typically defined as TSH values >0·4 and <4·5 μIU/ml, with both free triiodothyronine (FT3), free thyroxine (FT4) in the normal reference range. 
It should be noted however that the ideal range for TSH is still being debated, and that in some studies hypothyroidism may be diagnosed when the TSH is greater than 3.5 μIU/ml.  [Dr. Wentz comment- I completely agree. I would even venture to say that anything above a TSH of 2.0 μIU/ml may be too high for many of us]
But beyond the assessment of TSH, free t3 & free T4, more attention is being given to anti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin (anti-TG) antibodies and the role that those antibodies play in quality of life and various risk factors.
A 2016 study of Hashimoto’s thyroiditis patients that were “euthyroid” found that patients who had higher anti-TPO and anti-TG levels had significantly lower quality of life domain scores based on health-related quality of life questionnaire. The patients who had Hashimoto’s, but did not have elevated anti-TPO and anti-TG levels had a better quality of life than patients in the antibody-positive groups. 
A few years earlier, another study reported that Anti-TPO positivity (which they defined as TPO-Antibodies >100 IU/L) significantly predicted poorer psychosocial well-being and that high TPO-Abs are associated with poor physical and psychological well-being and appear to predict future health perception. 
Hashimoto’s thyroiditis patients with significantly increased levels of anti-thyroid peroxidase antibodies also displayed decreased neurocognitive function that measured processing speed, rule compliance, and quality of performance, even though they scored equally on neurocognitive executive function, attention, visual and verbal memory as well as acoustic working memory. 
It should also be pointed out that elevated thyroid peroxidase antibodies (TPO-Ab) in euthyroid women are associated with infertility, recurrent miscarriage (RM) and other pregnancy complications such as preterm birth. , , , 
Elevated anti-TPO and anti-TG antibody levels are not merely evidence that hypothyroidism was caused by autoimmune disease. Elevations of anti-TPO and anti-TG antibody levels are also indicative of an ongoing autoimmune process that continues to affect quality of life and increase risk factors for other conditions.
Hashimoto’s thyroiditis is an autoimmune thyroid disease. The first word, “autoimmune”, explains why the anti-TPO and anti-TG antibody levels have such a broad greater impact on quality of life.
The anti-TPO antibodies become elevated when they thyroid cells (thyrocytes) are irritated or inflamed by ongoing autoimmune disease and the thyroid peroxidase enzyme “leaks” out of the thyroid cell. Since the thyroid peroxidase enzyme is supposed to stay inside the thyroid cell, once it becomes exposed to the immune system the immune system creates anti-TPO antibodies. The anti-TG antibodies become elevated when the thyrocytes are actually destroyed and the thyroglobulin is exposed to the immune system. Elevated anti-TPO and anti-TG antibodies are a sign of ongoing autoimmune disease.
While restoring thyroid hormone levels with T4 & T3 is important, if the autoimmune disease is not addressed, then patients will not find the relief they were expecting from thyroid hormone therapy.
Several nutritional supplements have been discussed regarding their ability to lower anti-thyroid antibodies. A very recent 2016 paper reported that selenium supplementation reduced serum anti-TPO antibody levels after 3, 6, and 12 months in a levothyroxine-treated autoimmune thyroiditis group. The same paper reported that anti-TG antibody levels decreased at 3 months, but not at 6 or 12 months.  These findings are similar to other findings on using selenium therapy for lowering anti-TPO and anti-TG antibody levels. [Dr. Wentz note: For more information on selenium, you may want to see my Hashimoto’s and selenium article.]
Vitamin D insufficiency was also associated with autoimmune thyroid disease which includes Hashimoto’s thyroiditis. 
A 2016 paper showed that patients with autoimmune thyroid disease who had vitamin D deficiency had higher levels of anti-TPO antibodies. The anti-TPO antibodies levels were lowered with vitamin D in those patients who also had adequate T4 levels.  [Dr. Wentz note: I agree with this fully, I see that my clients that go into remission usually have their vitamin D levels optimized in the 60-80 range per blood testing. For more information on vitamin D, you may want to see my vitamin D and thyroid article.
One of the most interesting studies on lowering both anti-TPO and anti-TG antibodies involves the use of *Wobenzym®. Twenty patients were given 5 tablets of *Wobenzym® three times a day in addition to their levothyroxine. They were compared to twenty patients who were only given levothyroxine.
After three months, the patients taking Wobenzym® had a significant decrease in the levels of both anti-TPO and anti-TG antibodies. They also had improvement in symptoms, and a decrease of cholesterol and triglycerides levels, while patients on levothyroxine only had no significant changes.
Furthermore, in the patients also taking *Wobenzym®, the dosage of levothyroxine could be lowered after three months of treatment, and in some cases, it could be discontinued. With continuous Wobenzym® treatment improved clinical and laboratory parameters were maintained.
It appears that we have enough information to say that even if TSH, free T3 & free T4 levels are “euthyroid”, the quality of life is decreased if the anti-TPO and anti-TG antibodies remain elevated. Selenium and vitamin D supplementation may help lower anti-TPO antibodies if their need is indicated by deficiency. Wobenzym® can lower both anti-TPO and anti-TG antibodies.
Dr. Joseph J Collins, RN, ND is President and Co-founder of Your Hormones, Inc (www.YourHormones.com). He has been directly involved in advancing the practice of natural hormone health since 1993. His functional endocrinology model focuses on adrenal fatigue, hypothyroidism, menopause, andropause, PMS/PMDD, PCOS and blood sugar disorders. He has extensive experience in the advanced use of adaptogens to support and improve hormone function through the modulation of homeostasis regulatory systems which control hormone production and hormone function. In his work with Hashimoto’s Dr. Collins focuses on restoration of thyroid health through lifestyle, nutritional, herbal, and anti-inflammatory therapies.
 Temizkan S, Balaforlou B, Ozderya A, Avci M, Aydin K, Karaman S, Sargin M. Effects of thyrotrophin, thyroid hormones and thyroid antibodies on metabolic parameters in a euthyroid population with obesity. Clin Endocrinol (Oxf). 2016 Oct;85(4):616-23. PubMed PMID: 27150556.
 Robles-Osorio ML, Zacarías-Rangel V, García-Solís P, Hernández-Montiel HL, Solís JC, Sabath E. Prevalence of thyroid function test abnormalities and anti-thyroid antibodies in an open population in Central México. Rev Invest Clin. 2014 Mar-Apr;66(2):113-20. PubMed PMID: 24960320.
 Bektas Uysal H, Ayhan M. Autoimmunity affects health-related quality of life in patients with Hashimoto’s thyroiditis. Kaohsiung J Med Sci. 2016 Aug;32(8):427-33. PubMed PMID: 27523457.
 Müssig K, Künle A, Säuberlich AL, Weinert C, Ethofer T, Saur R, Klein R, Häring HU, Klingberg S, Gallwitz B, Leyhe T. Thyroid peroxidase antibody positivity is associated with symptomatic distress in patients with Hashimoto’s thyroiditis. Brain Behav Immun. 2012 May;26(4):559-63. PubMed PMID: 22285302.
 Leyhe T, Müssig K, Weinert C, Laske C, Häring HU, Saur R, Klingberg S, Gallwitz B. Increased occurrence of weaknesses in attention testing in patients with Hashimoto’s thyroiditis compared to patients with other thyroid illnesses. Psychoneuroendocrinology. 2008 Nov;33(10):1432-6. PubMed PMID: 18819753.
 Vissenberg R, van Dijk MM, Fliers E, van der Post JA, van Wely M, Bloemenkamp KW, Hoek A, Kuchenbecker WK, H R Verhoeve, H C J Scheepers, Rombout-de Weerd S, Koks C, Zwart JJ, Broekmans F, Verpoest W, Christiansen O, M Post, Papatsonis DN, Verberg MF, Sikkema J, Mol BW, Bisschop PH, Goddijn M. Effect of levothyroxine on live birth rate in euthyroid women with recurrent miscarriage and TPO antibodies (T4-LIFE study). Contemp Clin Trials. 2015 Aug 5. pii: S1551-7144(15)30061-6. PubMed PMID: 26255238.
 Lata K, Dutta P, Sridhar S, Rohilla M, Srinivasan A, Prashad GR, Shah VN, Bhansali A. Thyroid autoimmunity and obstetric outcomes in women with recurrent miscarriage: a case-control study. Endocr Connect. 2013 Jun 22;2(2):118-24. PubMed PMID: 23802061.
 Meena A, Nagar P. Pregnancy Outcome in Euthyroid Women with Anti-Thyroid Peroxidase Antibodies. J Obstet Gynaecol India. 2016 Jun;66(3):160-5. PubMed PMID: 27298524.
 Meena M, Chopra S, Jain V, Aggarwal N. The Effect of Anti-Thyroid Peroxidase Antibodies on Pregnancy Outcomes in Euthyroid Women. J Clin Diagn Res. 2016 Sep;10(9):QC04-QC07. PubMed PMID: 27790523.
 Wichman J, Winther KH, Bonnema SJ, Hegedüs L. Selenium Supplementation Significantly Reduces Thyroid Autoantibody Levels in Patients with Chronic Autoimmune Thyroiditis: A Systematic Review and Meta-Analysis. Thyroid. 2016 Dec;26(12):1681-1692. PubMed PMID: 27702392.
 Kim D. Low vitamin D status is associated with hypothyroid Hashimoto’s thyroiditis. Hormones (Athens). 2016 Jul;15(3):385-393. PubMed PMID: 27394703.
 Chaudhary S, Dutta D, Kumar M, Saha S, Mondal SA, Kumar A, Mukhopadhyay S.Vitamin D supplementation reduces thyroid peroxidase antibody levels in patients with autoimmune thyroid disease: An open-labeled randomized controlled trial. Indian J Endocrinol Metab. 2016 May-Jun;20(3):391-8. PubMed PMID: 27186560.
 Kvantchakhadze R.G. Wobenzym® in the complex treatment of autoimmune thyroiditis. International Journal on Immunorehabilitation, 2002, Vol. 4, No. 1, pp. 114. [Czech abstract, Russian abstract] Research and Therapeutic Center of Rheumatology, Tbilisi, Gruzia. VIII. International Congress on Immunorehabilitation, Allergy, Immunology, and Global Net], April 21-24, 2002, Cannes, France